Bone Metabolism-related Serum Biomarkers and Nutritional Markers for Bone Fractures in Living-donor Kidney Transplant Recipients.

IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
In vivo Pub Date : 2025-05-01 DOI:10.21873/invivo.13949
Shunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, Tatsuo Yoneda, Kenta Onishi, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Makito Miyake, Kazumasa Torimoto, Nobumichi Tanaka, Kiyohide Fujimoto
{"title":"Bone Metabolism-related Serum Biomarkers and Nutritional Markers for Bone Fractures in Living-donor Kidney Transplant Recipients.","authors":"Shunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, Tatsuo Yoneda, Kenta Onishi, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Makito Miyake, Kazumasa Torimoto, Nobumichi Tanaka, Kiyohide Fujimoto","doi":"10.21873/invivo.13949","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The clinical importance of fracture prevention in patients with end-stage renal disease is well-established. We investigated the roles of bone metabolism-related serum biomarkers and nutritional markers for fractures in Japanese living-donor kidney transplant recipients.</p><p><strong>Patients and methods: </strong>We included 204 consecutive patients who underwent kidney transplantation at Nara Medical University between 2003 and 2022 and retrospectively reviewed their medical charts. The cumulative incidence of fractures was investigated by focusing on bone metabolism-related serum biomarkers and nutritional markers, and related markers were explored.</p><p><strong>Results: </strong>The age at surgery in the fracture group was significantly higher than that in the no-fracture group (<i>p</i>=0.018). Patients with fractures had a significantly higher risk of mortality than those without fractures (<i>p</i>=0.0018); cardiovascular mortality was higher in the fracture group than in the non-fracture group (<i>p</i>=0.052). The cumulative incidence of fractures (median follow-up period, 98 months) was 4.6% at 1 year, 8.6% at 2 years, 12.3% at 3 years, and 15.5% at 5 years after transplant. Particularly, patients with a survival index <26.1 had a significantly higher risk of fracture (<i>p</i>=0.014). Serum intact parathyroid hormone level (a bone metabolism-related biomarker) and survival index (a nutritional marker) were independently related to fractures (<i>p</i>=0.046 and <i>p</i>=0.022, respectively).</p><p><strong>Conclusion: </strong>Serum intact parathyroid hormone level and the survival index may play important roles in determining the incidence of fractures in living donor kidney transplant recipients. Identifying patients at high risk of fractures and providing optimal intervention and education may contribute to improved and personalized management strategies.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1492-1504"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041986/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13949","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aim: The clinical importance of fracture prevention in patients with end-stage renal disease is well-established. We investigated the roles of bone metabolism-related serum biomarkers and nutritional markers for fractures in Japanese living-donor kidney transplant recipients.

Patients and methods: We included 204 consecutive patients who underwent kidney transplantation at Nara Medical University between 2003 and 2022 and retrospectively reviewed their medical charts. The cumulative incidence of fractures was investigated by focusing on bone metabolism-related serum biomarkers and nutritional markers, and related markers were explored.

Results: The age at surgery in the fracture group was significantly higher than that in the no-fracture group (p=0.018). Patients with fractures had a significantly higher risk of mortality than those without fractures (p=0.0018); cardiovascular mortality was higher in the fracture group than in the non-fracture group (p=0.052). The cumulative incidence of fractures (median follow-up period, 98 months) was 4.6% at 1 year, 8.6% at 2 years, 12.3% at 3 years, and 15.5% at 5 years after transplant. Particularly, patients with a survival index <26.1 had a significantly higher risk of fracture (p=0.014). Serum intact parathyroid hormone level (a bone metabolism-related biomarker) and survival index (a nutritional marker) were independently related to fractures (p=0.046 and p=0.022, respectively).

Conclusion: Serum intact parathyroid hormone level and the survival index may play important roles in determining the incidence of fractures in living donor kidney transplant recipients. Identifying patients at high risk of fractures and providing optimal intervention and education may contribute to improved and personalized management strategies.

活体肾移植受者骨折的骨代谢相关血清生物标志物和营养标志物
背景/目的:预防终末期肾脏疾病患者骨折的临床重要性已经确立。我们研究了骨代谢相关的血清生物标志物和营养标志物在日本活体肾移植受者骨折中的作用。患者和方法:我们纳入了2003年至2022年在奈良医科大学连续接受肾移植的204例患者,并回顾性回顾了他们的病历。以骨代谢相关的血清生物标志物和营养标志物为重点研究骨折的累积发生率,并对相关标志物进行探讨。结果:骨折组手术年龄明显高于非骨折组(p=0.018)。骨折患者的死亡率明显高于无骨折患者(p=0.0018);骨折组心血管死亡率高于非骨折组(p=0.052)。骨折的累积发生率(中位随访时间为98个月)在移植后1年为4.6%,2年为8.6%,3年为12.3%,5年为15.5%。特别是患者的生存指数p=0.014)。血清完整甲状旁腺激素水平(骨代谢相关生物标志物)和生存指数(营养标志物)与骨折独立相关(p=0.046和p=0.022)。结论:血清完整甲状旁腺激素水平和生存指数可能是决定活体肾移植受者骨折发生率的重要因素。识别骨折高危患者并提供最佳干预和教育可能有助于改进和个性化的管理策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
In vivo
In vivo 医学-医学:研究与实验
CiteScore
4.20
自引率
4.30%
发文量
330
审稿时长
3-8 weeks
期刊介绍: IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信